Andreas Halvorsen: portfolio of Viking Global Investors
Andreas Halvorsen leads Viking Global Investors, a hedge fund that analyzes stocks worldwide and combines long and short positions.
Source: 13F filing with the US Securities and Exchange Commission dated May 15, 2025. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included. Form 13F filingInvestment managers with discretion over at least 100 million USD in reportable US securities (mainly stocks and ETFs, plus options and convertible bonds) report their holdings to the SEC within 45 days after each quarter. Short positions, securities traded only abroad and cash are not included.Example: Positions as of 30 Sep, filed on 14 Nov → they are already six weeks old when published.More in the Academy: Glossary
You are looking at Q1 2025. Go to the latest filing (Q3 2026)
- Total value of stock positions
- 31.5B USD
- Positions
- 91
- Share of the ten largest
- 33.6%
The ten largest positions Q1 2025
- U.S. Bancorp 4.7%▲ +42.6%
- Charles Schwab Corporation 4.4%▲ +20.9%
- Bank of America 4.3%▲ +30.3%
- UnitedHealth Group 3.6%▲ +12.5%
- Intuit 3.3%▼ −0.7%
- Fortive 3.0%▼ −1.8%
- Meta Platforms 2.7%new
- Capital One 2.6%new
- Taiwan Semiconductor Manufacturing (ADR) 2.6%▲ +19.6%
- Api Group Corp 2.4%unchanged
Show all positions of this quarter
Choose a quarter (54 filings)
- Q3 2026
- Q2 2026
- Q1 2026
- Q4 2025
- Q3 2025
- Q2 2025
- Q1 2025
- Q4 2024
- Q3 2024
- Q2 2024
- Q1 2024
- Q4 2023
- Q3 2023
- Q2 2023
- Q1 2023
- Q4 2022
- Q3 2022
- Q2 2022
- Q1 2022
- Q4 2021
- Q3 2021
- Q2 2021
- Q1 2021
- Q4 2020
- Q3 2020
- Q2 2020
- Q1 2020
- Q4 2019
- Q3 2019
- Q2 2019
- Q1 2019
- Q4 2018
- Q3 2018
- Q2 2018
- Q1 2018
- Q4 2017
- Q3 2017
- Q2 2017
- Q1 2017
- Q4 2016
- Q3 2016
- Q2 2016
- Q1 2016
- Q4 2015
- Q3 2015
- Q2 2015
- Q1 2015
- Q4 2014
- Q3 2014
- Q2 2014
- Q1 2014
- Q4 2013
- Q3 2013
- Q2 2013
All positions Q1 2025
| Symbol | Weight | Shares | Reported value | Change | Held since |
|---|---|---|---|---|---|
| AMZN Amazon | 1.6% | 2,721,710 | 517.8M USD | +4.1% increased | Q2 2015 40 quarters |
| Bridgebio Pharma Inc | 2.4% | 22,055,375 | 762.5M USD | −12.2% reduced | Q2 2019 24 quarters |
| Adaptive Biotechnologies Cor | 0.7% | 29,993,708 | 222.9M USD | unchanged | Q2 2019 24 quarters |
| FTV Fortive | 3.0% | 12,950,122 | 947.7M USD | −1.8% reduced | Q3 2019 23 quarters |
| Api Group Corp | 2.4% | 21,537,518 | 770.2M USD | unchanged | Q2 2020 20 quarters |
| Royalty Pharma PLC | 1.0% | 10,563,939 | 328.9M USD | −13.5% reduced | Q2 2020 20 quarters |
| Pharvaris N V | 0.2% | 3,653,310 | 57.4M USD | unchanged | Q1 2021 17 quarters |
| Edgewise Therapeutics Inc | < 0.1% | 490,035 | 10.8M USD | −60.0% reduced | Q1 2021 17 quarters |
| Rallybio Corp | < 0.1% | 4,194,777 | 2.7M USD | unchanged | Q3 2021 15 quarters |
| Biomarin Pharmaceutical Inc | 2.4% | 10,800,059 | 763.5M USD | +2.8% increased | Q4 2021 14 quarters |
| Roivant Sciences Ltd | 1.5% | 46,013,752 | 464.3M USD | −3.8% reduced | Q4 2021 14 quarters |
| PGR Progressive Corporation | 1.0% | 1,068,406 | 302.4M USD | −50.8% reduced | Q1 2022 13 quarters |
| Pepgen Inc | < 0.1% | 1,482,434 | 2.1M USD | unchanged | Q2 2022 12 quarters |
| Trevi Therapeutics Inc | < 0.1% | 3,227,792 | 20.3M USD | −26.6% reduced | Q3 2022 11 quarters |
| CSX CSX Corporation | 1.6% | 17,068,769 | 502.3M USD | +16.3% increased | Q4 2022 10 quarters |
| Newamsterdam Pharma Company | 0.5% | 6,978,534 | 142.9M USD | unchanged | Q4 2022 10 quarters |
| PM Philip Morris International | 1.6% | 3,213,460 | 510.1M USD | −36.8% reduced | Q2 2023 8 quarters |
| USB U.S. Bancorp | 4.7% | 34,863,502 | 1.5B USD | +42.6% increased | Q4 2023 6 quarters |
| TMUS T-Mobile US | 1.3% | 1,565,894 | 417.6M USD | +156.5% increased | Q4 2023 6 quarters |
| HCA HCA Healthcare | 1.3% | 1,181,360 | 408.2M USD | +6.4% increased | Q4 2023 6 quarters |
| Regal Rexnord Corporation | 1.0% | 2,728,983 | 310.7M USD | +214.9% increased | Q4 2023 6 quarters |
| CPT Camden Property Trust | 1.1% | 2,788,789 | 341.1M USD | −17.1% reduced | Q1 2024 5 quarters |
| MSFT Microsoft | 0.8% | 683,918 | 256.7M USD | −71.4% reduced | Q1 2024 5 quarters |
| Equitable HLDGS Inc | 0.5% | 3,279,559 | 170.8M USD | +329.1% increased | Q1 2024 5 quarters |
| Integer HLDGS Corp | 0.4% | 1,177,273 | 138.9M USD | +1.9% increased | Q1 2024 5 quarters |
| Standard Biotools Inc | 0.2% | 58,651,170 | 63.3M USD | unchanged | Q1 2024 5 quarters |
| Oric Pharmaceuticals Inc | 0.1% | 6,572,700 | 36.7M USD | – | Q1 2024 5 quarters |
| Immunovant Inc | < 0.1% | 1,114,827 | 19.1M USD | −20.8% reduced | Q1 2024 5 quarters |
| INTU Intuit | 3.3% | 1,706,420 | 1.0B USD | −0.7% reduced | Q2 2024 4 quarters |
| NVDA Nvidia | 2.3% | 6,543,107 | 709.1M USD | +222.0% increased | Q2 2024 4 quarters |
| NFLX Netflix | 2.2% | 749,431 | 698.9M USD | +49.2% increased | Q2 2024 4 quarters |
| CVNA Carvana | 1.7% | 2,553,861 | 534.0M USD | +192.3% increased | Q2 2024 4 quarters |
| JPM JPMorgan Chase | 1.7% | 2,171,648 | 532.7M USD | −70.9% reduced | Q2 2024 4 quarters |
| ALL Allstate | 1.1% | 1,703,403 | 352.7M USD | −12.1% reduced | Q2 2024 4 quarters |
| DASH DoorDash | 1.1% | 1,858,037 | 339.6M USD | −62.5% reduced | Q2 2024 4 quarters |
| SHW Sherwin-Williams | 1.1% | 972,230 | 339.5M USD | +57.3% increased | Q2 2024 4 quarters |
| Spotify Technology S A | 0.3% | 192,877 | 106.1M USD | −87.5% reduced | Q2 2024 4 quarters |
| Inhibrx Biosciences Inc | < 0.1% | 1,787,705 | 25.0M USD | unchanged | Q2 2024 4 quarters |
| SCHW Charles Schwab Corporation | 4.4% | 17,716,717 | 1.4B USD | +20.9% increased | Q3 2024 3 quarters |
| BAC Bank of America | 4.3% | 32,199,070 | 1.3B USD | +30.3% increased | Q3 2024 3 quarters |
| V Visa Inc. | 2.4% | 2,125,091 | 744.8M USD | −39.2% reduced | Q3 2024 3 quarters |
| Flutter Entmt PLC | 1.8% | 2,554,206 | 565.9M USD | +36.7% increased | Q3 2024 3 quarters |
| SNPS Synopsys | 1.0% | 703,912 | 301.9M USD | −2.4% reduced | Q3 2024 3 quarters |
| BSX Boston Scientific | 0.8% | 2,376,764 | 239.8M USD | +9.4% increased | Q3 2024 3 quarters |
| Teva Pharmaceutical Inds Ltd | 0.5% | 10,125,478 | 155.6M USD | +55.7% increased | Q3 2024 3 quarters |
| Transunion | 0.4% | 1,336,984 | 111.0M USD | −67.4% reduced | Q3 2024 3 quarters |
| Biontech SE | 0.3% | 879,972 | 80.1M USD | −6.5% reduced | Q3 2024 3 quarters |
| ADSK Autodesk | 0.3% | 304,494 | 79.7M USD | −59.8% reduced | Q3 2024 3 quarters |
| Ginkgo Bioworks Holdings Inc | < 0.1% | 3,577,128 | 20.4M USD | unchanged | Q3 2024 3 quarters |
| MET MetLife | < 0.1% | 84,312 | 6.8M USD | −98.6% reduced | Q3 2024 3 quarters |
“Held since”: the first quarter from which the position appears in the 13F filing at every quarter end. It first appears at the end of that quarter – the filing gives neither date nor price, and trading between two quarter ends is not visible. “Or earlier”: the position was already in the first available filing (or the first one after a gap in filings). After a change of the security identifier (e.g. a renaming) the start may appear later.
Show more (up to 500) Shown: the 50 longest-held of 91 positions.
Breakdown by sector
- Financials 26.2%
- Technology 11.5%
- Consumer Discretionary 11.4%
- Health Care 7.1%
- Industrials 6.4%
- Communication Services 6.3%
- Real Estate 2.3%
- Consumer Staples 2.2%
- Materials 1.1%
- not in our coverage 25.6%
Sectors only for stocks we cover; the rest is grouped under “not in our coverage”.
How to read this page
- Weight: a position’s share of the total value of all reported stock positions in this quarter – options and bonds are not counted.
- Change: number of shares compared with the previous quarter. After a stock split we convert the previous quarter’s share count so that a split does not look like an increase; if a possible split cannot be confirmed, “–” is shown.
- Reported value: value of the position at quarter end as reported by the investor. The portfolio may have changed since then.
All superinvestor portfolios Screener: stocks held by superinvestors